|Videos|May 10, 2018

Placebo may be as good as omega-3s according to DREAM study findings

Penny Asbell, MD, professor of ophthalmology at Mount Sinai in New York, NY, discusses the Dry Eye Assessment and Management Study (DREAM) study and why omega-3s may be no better than a placebo in helping dry eye at ARVO 2018 in Honolulu.

The views expressed here belong to the author. They do not necessarily represent the views of Optometry Times or UBM Medica.

Penny Asbell, MD, professor of ophthalmology at Mount Sinai in New York, NY, discusses the Dry Eye Assessment and Management Study (DREAM) study and why omega-3s may be no better than a placebo in helping dry eye at ARVO 2018 in Honolulu.

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Placebo may be as good as omega-3s according to DREAM study findings

Related Content

Study finds that current ophthalmic patient letters may pose comprehension difficulty

WaveDȳn integrates with Bausch + Lomb and WAVE for scleral lens fitting

Remote Area Medical: Lindsay Elkins, OD, FAAO, on care for underserved communities

Study: Myopia develops in 1 in 4 nonmyopic male high school students in China

Identifying premyopia and encouraging preventative treatments

Latest CME

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

EyeCon 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

WaveDȳn integrates with Bausch + Lomb and WAVE for scleral lens fitting

Remote Area Medical: Lindsay Elkins, OD, FAAO, on care for underserved communities

Study finds that current ophthalmic patient letters may pose comprehension difficulty

What Lytenava FDA approval means for compounded bevacizumab in AMD

Contact lenses of the future